Lucía
López Corral
Profesora Asociada CC. Salud
Teresa
Caballero Velázquez
Publicaciones en las que colabora con Teresa Caballero Velázquez (12)
2023
-
Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4057-4067
2022
-
Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment
Transplantation and Cellular Therapy, Vol. 28, Núm. 5, pp. 258.e1-258.e8
2020
-
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
Bone Marrow Transplantation, Vol. 55, Núm. 2, pp. 419-430
-
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
Bone Marrow Transplantation, Vol. 55, Núm. 3, pp. 641-648
2019
-
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1703-1712
-
Vitamin D modifies the incidence of graft-versus-host disease after allogeneic stem cell transplantation depending on the Vitamin D Receptor (VDR) polymorphisms
Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4616-4623
2018
-
Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting
Medical Oncology, Vol. 35, Núm. 6
2016
-
Immunomodulatory effect of Vitamin D after allogeneic stem cell transplantation: Results of a prospective multicenter clinical trial
Clinical Cancer Research, Vol. 22, Núm. 23, pp. 5673-5681
2015
-
GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT
Bone Marrow Transplantation, Vol. 50, Núm. 1, pp. 121-126
2014
-
Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585
2013
-
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients
British Journal of Haematology, Vol. 162, Núm. 4, pp. 474-482
2011
-
Helicobacter pylori Infection and Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation, Vol. 17, Núm. 5, pp. 765-769